361 related articles for article (PubMed ID: 30412106)
21. A decade of immune-checkpoint inhibitors in cancer therapy.
Robert C
Nat Commun; 2020 Jul; 11(1):3801. PubMed ID: 32732879
[TBL] [Abstract][Full Text] [Related]
22. The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review.
Moujaess E; Haddad FG; Eid R; Kourie HR
Immunotherapy; 2019 Nov; 11(16):1409-1422. PubMed ID: 31621445
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic Benefits of Ipilimumab among Japanese Patients with Nivolumab-Refractory Mucosal Melanoma: A Case Series Study.
Saijo K; Imai H; Ouchi K; Okada Y; Sato Y; Komine K; Takahashi M; Takahashi S; Shirota H; Takahashi M; Ishioka C
Tohoku J Exp Med; 2019 May; 248(1):37-43. PubMed ID: 31105123
[TBL] [Abstract][Full Text] [Related]
24. Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade.
Gambichler T; Strutzmann S; Tannapfel A; Susok L
BMC Cancer; 2017 May; 17(1):327. PubMed ID: 28499411
[TBL] [Abstract][Full Text] [Related]
25. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.
Fuu T; Iijima K; Kusama Y; Otsuki T; Kato H
J Med Case Rep; 2022 May; 16(1):193. PubMed ID: 35581611
[TBL] [Abstract][Full Text] [Related]
26. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
27. Synchronous Primary Endometrial Carcinoma and Metastatic Malignant Melanoma in an Ovarian Cystic Teratoma.
Genç M; Sivrikoz O; Genç B; Kurt S; Çelik E
Turk Patoloji Derg; 2015; 31(3):215-8. PubMed ID: 24715550
[TBL] [Abstract][Full Text] [Related]
28. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
29. Primary malignant melanoma arising in a cystic teratoma of the ovary.
Tsukamoto N; Matsukuma K; Matsumura M; Kamura T; Matsuyama T; Kinjo M
Gynecol Oncol; 1986 Mar; 23(3):395-400. PubMed ID: 3957127
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.
Hao C; Tian J; Liu H; Li F; Niu H; Zhu B
Medicine (Baltimore); 2017 Jun; 96(26):e7325. PubMed ID: 28658143
[TBL] [Abstract][Full Text] [Related]
31. What do we know about cancer immunotherapy? Long-term survival and immune-related adverse events.
Miranda Poma J; Ostios Garcia L; Villamayor Sanchez J; D'errico G
Allergol Immunopathol (Madr); 2019; 47(3):303-308. PubMed ID: 29983240
[TBL] [Abstract][Full Text] [Related]
32. The next generation of immunotherapy: keeping lung cancer in check.
Somasundaram A; Burns TF
J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
[TBL] [Abstract][Full Text] [Related]
33. Checkpoint Blockade in Melanoma Patients With Underlying Chronic Lymphocytic Leukemia.
Smithy JW; Pianko MJ; Maher C; Postow MA; Shoushtari AN; Momtaz P; Chapman PB; Wolchok JD; Park JH; Callahan MK
J Immunother; 2021 Jan; 44(1):9-15. PubMed ID: 33290361
[TBL] [Abstract][Full Text] [Related]
34. Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05.
Park JH; You GL; Ahn MJ; Kim SW; Hong MH; Han JY; Ock CY; Lee JS; Oh IJ; Lee SY; Kim CH; Min YJ; Choi YH; Ryu JS; Park SH; Ahn HK; Shim BY; Lee KH; Lee SY; Kim JS; Yi J; Choi SK; An H; Kang JH
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2459-2469. PubMed ID: 33523301
[TBL] [Abstract][Full Text] [Related]
35. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis.
Su Q; Zhu EC; Wu JB; Li T; Hou YL; Wang DY; Gao ZH
Front Immunol; 2019; 10():108. PubMed ID: 30778352
[No Abstract] [Full Text] [Related]
36. Cancer immunology and melanoma immunotherapy.
Linck RDM; Costa RLP; Garicochea B
An Bras Dermatol; 2017; 92(6):830-835. PubMed ID: 29364441
[TBL] [Abstract][Full Text] [Related]
37. Squamous cell carcinoma arising in an ovarian mature cystic teratoma: a case report.
Shariat-Torbaghan S; Emami-Aleagha M; Sedighi S; Azadbakht F; Keshvari A; Hajarizadeh B; Rosai J
Arch Iran Med; 2009 Mar; 12(2):186-9. PubMed ID: 19249893
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy in Nonmelanoma Skin Cancer.
Bassas Freixas P; Aparicio Español G; García-Patos Briones V
Actas Dermosifiliogr (Engl Ed); 2019 Jun; 110(5):353-359. PubMed ID: 30837075
[TBL] [Abstract][Full Text] [Related]
39. Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations.
Ascierto PA; Capone M; Grimaldi AM; Mallardo D; Simeone E; Madonna G; Roder H; Meyer K; Asmellash S; Oliveira C; Roder J; Grigorieva J
J Immunother Cancer; 2019 Mar; 7(1):91. PubMed ID: 30925943
[TBL] [Abstract][Full Text] [Related]
40. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.
Bellmunt J; Powles T; Vogelzang NJ
Cancer Treat Rev; 2017 Mar; 54():58-67. PubMed ID: 28214651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
